QYUNS-B: QX004N enters Phase III clinical trial and receives payment from HANSOH PHARMA

Zhitong
2025.08.05 11:12
portai
I'm PortAI, I can summarize articles.

QYUNS-B announced that its interleukin 23p19 inhibitor QX004N has entered Phase III clinical trials and has signed an exclusive licensing agreement with HANSOH PHARMA, covering research and development, production, and commercialization in mainland China, Taiwan, Hong Kong, and Macau. The company has received milestone and other payments of RMB 58 million from HANSOH PHARMA

According to the Zhitong Finance APP, QYUNS-B (02509) announced that the company is developing an interleukin 23p19 subunit (IL23p19) inhibitor QX004N for the treatment of psoriasis (Ps) and Crohn's disease (CD). In April 2024, the company signed an exclusive external licensing agreement with HANSOH PHARMA GROUP CO., LTD. (03692.HK) through its wholly-owned subsidiary HANSOH (Shanghai) Health Technology Co., Ltd. for the research and development, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macau.

The announcement stated that QX004N has recently entered Phase III clinical trials, becoming the fourth product in the company's pipeline to successfully enter the Phase III stage.

Recently, the company has received milestone and other payments totaling RMB 58 million from HANSOH PHARMA under the licensing agreement for the Phase III trial of Ps

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.